The journal of nutrition, health & aging

, Volume 17, Issue 7, pp 612–618

Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US task force recommendations

Authors

  • B. Vellas
    • Inserm UMR1027 Inserm
    • University of Toulouse III
    • GerontopoleToulouse University Hospital
  • M. Pahor
    • University of Florida
  • T. Manini
    • University of Florida
  • D. Rooks
    • Novartis Institutes for Biomedical Research
  • J. M. Guralnik
    • University of Maryland School of Medicine
  • J. Morley
    • St. Louis University Medical School
  • S. Studenski
    • University of Pittsburgh
  • W. Evans
    • GlaxoSmithKline
  • C. Asbrand
    • Sanofi-Aventis Deutschland GmbH
  • R. Fariello
    • Neurotune AG
  • S. Pereira
    • Abbott Nutrition R&D
  • Y. Rolland
    • Inserm UMR1027 Inserm
    • University of Toulouse III
    • GerontopoleToulouse University Hospital
  • G. Abellan Van Kan
    • GerontopoleToulouse University Hospital
  • M. Cesari
    • Inserm UMR1027 Inserm
    • University of Toulouse III
    • GerontopoleToulouse University Hospital
  • W. M. C. Chumlea
    • Lifespan Health Research Center, Boonshoft School of MedicineWright State University
  • R. Fielding
    • Jean Mayer USDA Human Nutrition Research Center on AgingTufts University
Article

DOI: 10.1007/s12603-013-0362-7

Cite this article as:
Vellas, B., Pahor, M., Manini, T. et al. J Nutr Health Aging (2013) 17: 612. doi:10.1007/s12603-013-0362-7

Abstract

An international task force of academic and industry leaders in sarcopenia research met on December 5, 2012 in Orlando, Florida to develop guidelines for designing and executing randomized clinical trials of sarcopenia treatments. The Task Force reviewed results from previous trials in related disease areas to extract lessons relevant to future sarcopenia trials, including practical issues regarding the design and conduct of trials in elderly populations, the definition of appropriate target populations, and the selection of screening tools, outcome measures, and biomarkers. They discussed regulatory issues, the challenges posed by trials of different types of interventions, and the need for standardization and harmonization. The Task Force concluded with recommendations for advancing the field toward better clinical trials.

Key words

Sarcopeniaclinical trialskeletal musclefrailtyintervention

Copyright information

© Serdi and Springer-Verlag France 2013